EcoR1 Capital LLC Has $7.73 Million Position in Metsera Inc. $MTSR

EcoR1 Capital LLC boosted its position in shares of Metsera Inc. (NASDAQ:MTSR) by 443.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 271,529 shares of the company’s stock after buying an additional 221,529 shares during the quarter. Metsera makes up approximately 0.5% of EcoR1 Capital LLC’s holdings, making the stock its 28th largest holding. EcoR1 Capital LLC owned about 0.26% of Metsera worth $7,725,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of MTSR. BNP Paribas Financial Markets increased its stake in shares of Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock valued at $46,000 after buying an additional 800 shares during the period. Virtus Investment Advisers LLC bought a new position in Metsera in the second quarter valued at about $77,000. Strs Ohio acquired a new stake in Metsera in the first quarter worth about $76,000. Police & Firemen s Retirement System of New Jersey raised its holdings in Metsera by 32.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 4,293 shares of the company’s stock worth $122,000 after purchasing an additional 1,056 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in Metsera during the 2nd quarter worth about $122,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MTSR. Bank of America raised their target price on shares of Metsera from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Wells Fargo & Company lowered shares of Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price objective on the stock. in a report on Tuesday, September 30th. Wall Street Zen raised shares of Metsera from a “sell” rating to a “hold” rating in a report on Wednesday, October 1st. Leerink Partnrs cut shares of Metsera from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 24th. Finally, Leerink Partners reissued a “market perform” rating and issued a $57.00 price target (down previously from $77.00) on shares of Metsera in a research note on Wednesday, September 24th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Metsera currently has an average rating of “Hold” and a consensus price target of $55.75.

Metsera Price Performance

Metsera stock opened at $70.50 on Friday. The firm has a market capitalization of $7.42 billion and a price-to-earnings ratio of -11.16. The company’s 50 day simple moving average is $64.17 and its 200 day simple moving average is $45.24. Metsera Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $83.86.

Metsera (NASDAQ:MTSR) last issued its earnings results on Wednesday, November 12th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.55).

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.